- Home
- KC vs VKTX Comparison
KC vs VKTX Comparison
Compare KC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | VKTX |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KC | VKTX |
|---|---|---|
| Price | $14.43 | $28.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $17.50 | ★ $87.07 |
| AVG Volume (30 Days) | 1.3M | ★ 3.2M |
| Earning Date | 03-18-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,268,313,014.00 | N/A |
| Revenue This Year | $25.79 | N/A |
| Revenue Next Year | $17.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.11 | N/A |
| 52 Week Low | $10.29 | $18.92 |
| 52 Week High | $22.26 | $43.15 |
Technical Indicators
Market Signals| Indicator | KC | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 40.07 |
| Support Level | $12.75 | $25.77 |
| Resistance Level | $13.47 | $29.70 |
| Average True Range (ATR) | 0.61 | 1.64 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 81.02 | 30.21 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.